卒中后延长心脏节律监测对心房颤动检出效果的真实认识
本文综述了亚临床心房颤动(SCAF)与卒中风险及口服抗凝获益的现有证据,指出SCAF在延长心脏监测中极常见且可能为生理性,其相关卒中风险低于临床诊断的心房颤动,抗凝对卒中风险的任何获益可能被出血风险增加所抵消(无净获益),卒中后SCAF筛查与预防策略的净获益尚未确立。
要点
- SCAF在延长心脏监测中极常见,有时可能为生理性发现。
- SCAF相关卒中风险低于临床诊断的心房颤动。
- 抗凝对SCAF卒中风险的获益可能被出血风险增加所抵消,无净获益。
核心结论
- 尽管对SCAF进行了广泛筛查和治疗(尤其在二级卒中预防中),该实践的净获益尚未确立。
- SCAF相关卒中风险低于临床诊断的心房颤动,抗凝的任何卒中风险获益可能被出血风险增加所抵消(无净获益)。
研究设计与样本
- 本文为综述,基于对临床诊断心房颤动相关卒中风险与口服抗凝获益的现有研究,以及近期SCAF研究的汇总分析。
主要发现
- SCAF定义为延长心脏监测问询中发现的心房颤动,常无症状且持续时间短,与窦性心律相比卒中风险增加,并可能进展为临床心房颤动。
- 近期SCAF研究提供新见解:SCAF极常见且有时可能为生理性发现;SCAF相关卒中风险低于临床诊断的心房颤动;抗凝对卒中风险的任何获益可能被出血风险增加所抵消(无净获益)。
关键数值与推荐
- SCAF定义为延长心脏监测问询中发现的心房颤动。
- SCAF常无症状且持续时间短,与窦性心律相比卒中风险增加,并可能进展为临床心房颤动。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The bulk of the current knowledge on atrial fibrillation (AF)-associated stroke risk and benefit of oral anticoagulation derives from studies on patients with clinically diagnosed AF. Subclinical AF (SCAF), defined as AF discovered during the interrogation of prolonged heart monitoring, is often asymptomatic and short-lasting, is associated with increased stroke risk compared with sinus rhythm, and may progress to clinical AF. Despite the extensive screening for and treatment of SCAF, especially in secondary stroke prevention, the net benefit of this practice is not established. Recent studies of SCAF have provided new insights: (1) SCAF is extremely common and may sometimes indicate physiological findings, (2) the stroke risk associated with SCAF is lower than that of clinically detected AF, and (3) any benefit on stroke risk may be countered by increased bleeding risk (no net benefit). How should we interpret the latest knowledge in the setting of poststroke AF screening and prevention?
引用
- Ihle-Hansen H, Hagberg G, Ihle-Hansen H, et al. What Do We Really Know About the Effect of Prolonged Heart Rhythm Monitoring After Stroke? Stroke. 2024. PMID: 38456295. doi:10.1161/STROKEAHA.123.045843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。